Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials-Reference-Cited by-同舟云学术

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

Published:2015-07 Issue:7 Volume:16 Page:848-858
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Bernhard Jürg,Luo Weixiu,Ribi Karin,Colleoni Marco,Burstein Harold J,Tondini Carlo,Pinotti Graziella,Spazzapan Simon,Ruhstaller Thomas,Puglisi Fabio,Pavesi Lorenzo,Parmar Vani,Regan Meredith M,Pagani Olivia,Fleming Gini F,Francis Prudence A,Price Karen N,Coates Alan S,Gelber Richard D,Goldhirsch Aron,Walley Barbara A

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer;Pagani;N Engl J Med,2014

2. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials;Regan;Breast,2013

3. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial;Fallowfield;J Clin Oncol,2004

4. Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer;Cella;Breast Cancer Res Treat,2006

5. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer;Fallowfield;J Clin Oncol,2006

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ovarian Suppression: Early Menopause, Late Effects;Current Oncology Reports;2024-01-02

2. Role of ovarian suppression in adjuvant treatment of breast cancer;Medical alphabet;2023-12-04

3. Efficacy and safety of diphereline 11.25 mg, microrelin 11.25 mg, and microrelin 3.75 mg in premenopausal patients with breast cancer: a non-inferiority randomized clinical trial;BMC Cancer;2023-11-10

4. Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome;Cancer Treatment Reviews;2023-11

5. Whole Breast Irradiation in Comparison to Endocrine Therapy in Early Stage Breast Cancer—A Direct and Network Meta-Analysis of Published Randomized Trials;Cancers;2023-08-30